when necessary. It is well known that long term stability is difficult to achieve because of unexpected fluctuations of the INR values in patients, which can be attributed to numerous factors including change in diet, poor adherence to treatment, alcohol consumption, seasonal variations, and drug to drug interactions [9, 10] .
The aim of this study is to evaluate the level of anticoagulation control in patients treated with VKA for various indications in a clinical practice setting and to explore the relationship between anticoagulation control and adherence to VKA treatment.
PatIents and methods

Sources of data
The data we used were retrieved from three different administrative databases of three Local Health Units (LHU) located in the centre (1) CliCon S.r.l. Health, Economics and Outcomes Research, Ravenna (2) In the same period all determinations of the international normalised ratio (INR) were collected. The parameters evaluated were anticoagulation control and adherence to VKA treatment. The survey showed that only 47.9% and 56.3% of INR determinations, in VKA naïve and established patients respectively, were into the recommended range (2.0-3.0). Moreover, the percentage of INR determination below the recommended range was higher than the percentage of INR determination above the recommended range for both naïve and established patients. Moreover, adherence to VKA treatment was poor both in naïve and established patients and, consequently, anticoagulation control is poor. Also in patients with the highest adherence to VKA treatment, only about 60% of INR determinations were into the recommended range. Our findings evidence that the anticoagulation control in clinical practice settings is still unsatisfactory and it is necessary to evaluate interventions to increase the amount of time at which patients' INR are within the recommended range. 
Keywords
Adherence to treatment
Adherence to treatment was calculated as the sum of "adequately dosed" days for VKAs divided by the duration in days of the follow up period (365) multiplied by 100. Tablets in each prescription were divided by the elapsed time in days up to the following prescription. If the average number of tablets per day was in the range 0.5-2.0, the number of days up to the following prescription was classified as "adequately dosed" for VKAs. Tablets prescribed into the last prescription contributed only for those accountable until the end the follow up period.
Anticoagulation control
Anticoagulation control was calculated as the sum of INR determinations in the range 2.0-3.0 divided by the overall number of INR determinations multiplied by 100. In order to avoid potential confounding effects of low or high number of INR determinations, the relationship between anticoagulation control and adherence to treatment was studied also in patients within 25 and 75 percentile of INR determinations.
and north of Italy and including approximately 774,000 beneficiaries: "Health-assisted subjects' Database", containing patients' demographic data; "Medications Prescription Database", providing information for each medication prescription such as the prescribing physician's number, the Anatomical-TherapeuticChemical (ATC) code of the drug purchased, the number of packs, the number of units per pack, the dosages, the unit cost per pack and the prescription date; and "Laboratory test values database", which includes the date of administration for laboratory test, the type of laboratory test and description, and the laboratory test result. The patient code in each database permitted electronic linking among all three databases. In order to guarantee patient privacy, each subject was assigned an anonymous univocal numeric code. The researchers weren't provided with identifiers related to patients. The local Ethics Committee of each participating LHUs approved this study.
Cohort definition
This was a retrospective cohort study, which included all relevant medication prescription and laboratory test data over the study period for both naïve and established VKA users. Patients were enrolled if they had filled at least one prescription for VKAs (ATC code B01AA) between January 1 established. Naïve patients were younger than established ones (73.5 ± 12.0 versus 75.8 ± 9.9) and prevalently male (51.0%). Concurrent antithrombotic drugs and frequency of INR determinations are presented in Table I . Most patients showed no concurrent antithrombotic drug combined with VKAs both in naïve (62.5%) and in established patients (59.5%). Concurrent use of heparins or antiplatelet agents resulted, respectively, in 12.4% and 20.2% of naïve patients and in 7.6% and 8.1% of established patients (Table I ). The median number of INR determination was 17 (11-26) in the overall included cohort, ranging from 18 (8-28) in naïve patients to 16 (12-25) in established patients (Table I ). On average, in the year of follow up 47.9% and 56.3% of INR determinations in naïve and established patients, respectively, resulted within the recommended range (2.0-3.0) (Table II) .
Mean percentage of INR determination below the recommended range was higher than mean percentage of INR determination above the recommended range for both naïve and established patients (Table II) .
Statistical analysis
Data were summarised as mean ± standard deviation (SD) or median (25-75 percentile) for continuous variable and as numbers (percentages) of subjects for categorical variables. Pearson's chi-square and one-way ANOVA tests were used to evaluate differences in baseline characteristics across adherence levels. Multivariable median regression was used to estimate beta coefficient (β) and 95% confidence intervals (CIs) of achieving anticoagulation control as a function of adherence categories. To adjust for potential confounders, in the multivariable model we included age, gender, and presence of thrombolytic drugs (yes/no) -at least two prescriptions in the follow up period of heparin (ATC code B01AB), antiplatelet agents (ATC code B01AC), and concurrent antithrombotic therapy (ATC code B01AD -enzymes, ATC code B01AE -direct thrombin inhibitors, ATC code B01AX -other antithrombotic agents). Two-tailed p-values less than 0.05 were considered statistically significant. All analyses were conducted using SPSS for Windows, version 15.0.
results
A total of 16,339 patients were enrolled in the study. Of whom, 5,506 patients (33.7% of enrolled subjects) were excluded: 82 (0.5%) because they were transferred to another LHU, 1,421 (8.7%) because they died and 4,003 (24.5%) because they had not INR determinations during the follow up period. A total of 10,833 patients were included in the study, 5,531 men (51.0%) and 5,302 women (49.0%), with a mean age of 75.1 ± 10.6 (range 18-101) years. Most of the patients were aged 70-89 years old (67.6% of men and 75.9% of women). Among included patients, 3,075 (28.4%) were classified as naïve and 7,758 (71 
Adherence to treatment and anticoagulation control in vitamin K antagonists-treated patients
When only patients with a number of INR determinations within 25 and 75 percentile were studied (Table IV) , mean percentage of INR determinations within the recommended range (2.0-3.0) varied from 46.2% in naïve patients with lowest adherence (0-9%) to 59.5% in those with highest adherence (> 90%) and from 53.1% in established patients with lowest adherence (0-9%) to 62.4% in those with highest adherence (> 90%). Results are presented in Figure 2 . Overall, 55,6% of the patients in analysis had less than 60% of INR determinations within the recommended range (2.0-3.0) during the year of follow up.
The multivariable median regression showed that anticoagulation control was related to adherence with VKA treatment (+0.14% of the percentage of INR in range 2-3 for an increment of 1% of VKA treatment coverage, p < 0.001), use of heparins (-10.70%, p < 0.001), antiplatelet agents (-6.14%, p < 0.001), or concurrent antithrombotic therapy (-15.81%, p < 0.001), and to number of INR determinations (+0.06% of the percentage of Adherence to VKA treatment was poor both in naïve and established patients but higher in established patients (53.7 ± 33.5% versus 41.6 ± 35.0%). According to the distribution by levels of adherence (Table III) , highest frequency of patients was displayed by the lowest category of adherence in naïve patients (27.0%) and by the highest category of adherence in established patients (23.2%).
Both naïve and established patients seemed to be homogenously distributed into different levels of adherence. Similar results were obtained when only patients with a number of INR determinations within 25 and 75 percentile were studied (Table IV) .
Mean percentage of INR determinations within the recommended range (2.0-3.0) varied from 34.3% in naïve patients with lowest adherence (0-9%) to 57.8% in those with highest adherence (> 90%) and from 47.6% in established patients with lowest adherence (0-9%) to 60.0% in those with highest adherence (> 90%) (Table  III) . Results are presented in Figure 1 . Table V) .
dIscussIon
This study, in our knowledge the first in Italy to provide an evaluation about the degree of anticoagulation control in a large cohort of VKA treated patients as well as to explore the relationship between adherence to VKA treatment and anticoagulation control, showed that only 47.9% and 56.3% of INR determinations, in naïve and established patients respectively, were into the recommended range. Moreover, the percentage of INR determination below the recommended range was higher than the percentage of INR determination above the recommended range for both naïve and established patients. Other studies, performed in a clinical practice settings, have shown that patients were prone to spend more time with ratio below than above the therapeutic range [11, 12] . These findings could be attributed to the effects of low dose of VKA treatment as a consequence of an overestimate risk of haemorrhage: physicians estimate the rate of intracranial bleeding related to the use of warfarin ten times higher than the rate reported in the literature [13] . A recent systematic review [8] found a strong association between anticoagulation intensity and outcomes: the risk of haemorrhage significantly increased when the INR exceeded 3, while the risk of thromboembolism was greatest when the INR was below 2. When both haemorrhagic and thromboembolic events are considered, the data show that patients were safer with a ratio slightly above, rather than below, the therapeutic range of 2-3 [8] . Physicians should be aware of this finding and should adjust their clinical practices accordingly, by aggressively correcting subtherapeutic ratios and avoiding overreaction to ratios that narrowly exceed 3.
Adherence to VKA treatment, the second aspect that we analysed, was poor both in naïve and established patients and, consequently, the 
